Clinique Des Cedres.
- Address
- 21 Rue Albert Londres, 38130 Échirolles, France
Digestive System Diseases – Crohn’s Disease
Clinique Des Cedres is conducting studies aimed at improving outcomes for patients with Crohn’s disease, including those with moderate to severe activity. The trials assess new therapeutic agents for achieving clinical remission and endoscopic improvement.
- Evaluation of novel oral inhibitor for remission at 12 and 52 weeks
- Comparison of clinical remission scores and stool frequency
- Assessment of endoscopic response as a measure of healing
These efforts reflect the site’s commitment to advancing treatment options for inflammatory bowel disease within the digestive specialty.
Immune System Diseases – Ulcerative Colitis and Obesity
Research at the site also targets the intersection of ulcerative colitis and metabolic health, testing combined biologic and weight‑loss therapies to achieve both disease control and weight reduction.
- Combination of an anti‑IL‑23 antibody with a dual‑GIP/GLP‑1 agonist
- Simultaneous goals of clinical remission, endoscopic remission, and weight loss
- Inclusion of adult and adolescent participants for broader applicability
The study design explores how immune modulation can be paired with metabolic interventions to improve patient quality of life.
Integrated Digestive‑Immune Research
Across its portfolio, Clinique Des Cedres evaluates emerging agents such as icotrokinra for both Crohn’s disease and ulcerative colitis, focusing on induction and maintenance of remission.
- Induction studies measuring early clinical response
- Maintenance trials assessing sustained remission
- Adolescent-focused research to address pediatric needs
This integrated approach underscores the center’s expertise in bridging digestive and immune therapeutics.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Janssen Cilag International3active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinique Des Cedres.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Janssen Cilag International | Phase IV | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| ICOTROKINRA | 2 | Unknown | 2025-12-03 | 2025-12-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.